Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 1/2 1

Status

Completed 2

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Plasma cell 3Lymphoid 2

Conditions

Lymphoma, Mantle-Cell 66Lymphoma 65Lymphoma, Non-Hodgkin 43Lymphoma, Follicular 42Precursor Cell Lymphoblastic Leukemia-Lymphoma 41Lymphoma, Large B-Cell, Diffuse 34Waldenstrom Macroglobulinemia 33Lymphoma, B-Cell, Marginal Zone 30Leukemia, Lymphocytic, Chronic, B-Cell 28Recurrence 18Multiple Myeloma 17Hodgkin Disease 17Lymphoma, B-Cell 14Leukemia, Myeloid, Acute 14Burkitt Lymphoma 14Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 13Lymphoma, Large-Cell, Anaplastic 13Leukemia 12Immunoblastic Lymphadenopathy 12Mycosis Fungoides 11Lymphoma, T-Cell, Cutaneous 11Lymphoma, Large-Cell, Immunoblastic 11Sezary Syndrome 10Lymphoma, T-Cell, Peripheral 10Neoplasms, Plasma Cell 9Neoplasms 9Lymphoma, T-Cell 8Myelodysplastic Syndromes 7Lymphoma, Extranodal NK-T-Cell 7Leukemia, Myelogenous, Chronic, BCR-ABL Positive 6

Interventions

Cyclophosphamide 8fludarabine 4Rituximab 4Melphalan 3tetulomab tetraxetan lu-177 2ponatinib 2fludarabine phosphate 2entrectinib 2atezolizumab 2alectinib 2Whole-Body Irradiation 2Vincristine 2Tacrolimus 2Prednisone 2Peripheral Blood Stem Cell Transplantation 2Patient Reported Outcome Measures 2Mycophenolic Acid 2Mesna 2Lutetium 2Etoposide 2Doxorubicin 2Busulfan 2Brentuximab Vedotin 2Bortezomib 2Bone Marrow Transplantation 2trametinib 1pertuzumab 1penpulimab 1pembrolizumab 1ibritumomab tiuxetan 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Neoplasms by Histologic Type × Bortezomib × Lymphoid × Clear all
NCT01183949 2024-08-02

Effect of AT7519M Alone and AT7519M Plus Bortezomib in Patients With Previously Treated Multiple Myeloma

Astex Pharmaceuticals, Inc.

Phase 1/2 Completed
18 enrolled
LymphoidPlasma cell

Blood Protein Disorders, Hematologic Diseases, Hemorrhagic Disorders, Immune System Diseases, Immunoproliferative Disorders, Lymphoproliferative Disorders, Multiple Myeloma, Neoplasms, Neoplasms by Histologic Type, Paraproteinemias, Hemostatic Disorders, Neoplasms, Plasma Cell

NCT00773747 2021-04-30

Study of Vorinostat (MK-0683) or Placebo, in Combination With Bortezomib in Participants With Multiple Myeloma (MK-0683-088 AMN)

Merck Sharp & Dohme LLC

Phase 3 Completed
637 enrolled 15 charts
LymphoidPlasma cell

Blood Protein Disorders, Cardiovascular Diseases, Hematologic Diseases, Hemorrhagic Disorders, Immune System Diseases, Immunoproliferative Disorders, Lymphoproliferative Disorders, Multiple Myeloma, Neoplasms, Neoplasms by Histologic Type, Paraproteinemias, Vascular Diseases, Hemostatic Disorders, Neoplasms, Plasma Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡